Angle Health's $600m deal pays early holders more than it funds growth

Angle Health, a San Francisco company that sells health plans to small and midsize employers, said on Friday, September 18, that it had agreed a $600m equity financing at a valuation of $2.7bn. Only $200m of that is new capital: a Series C led by the London growth investor Vitruvian Partners, with Town Hall Ventures joining as a new backer and existing investors Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator also taking part. The other $400m is a tender offer that lets earlier shareholders and employees sell stock. The company expects the transaction to close later this month.

The structure is the story. Angle Health is one of a small number of venture-backed insurers that says it makes money, and its investors have chosen to use this round mainly to return cash to people who backed it early. That tells founders something about how growth investors are now pricing companies that sit between software and regulated financial risk, and about the growing role of secondary sales in private markets.

What Angle Health sells

The company, which went through Y Combinator in its winter 2020 batch, helps small businesses buy and run so-called level-funded health plans. These sit between a traditional fully insured policy, where the carrier carries all of the risk for a fixed premium, and a self-funded plan, where the employer pays claims directly. Angle Health underwrites its own cover and wraps it in software that connects to payroll and HR systems. Its tools include a quoting product called Benefit Builder, which it says lets brokers produce underwritten proposals in minutes, a Quote-to-Card product that takes brokers from census data to underwriting and group implementation, and a Health Scorecard that brokers reach through Benefit Builder. It also runs care programmes aimed at expensive categories such as specialty medications, infusions, outpatient surgery and radiology.

The founders, chief executive Ty Wang and chief technology officer Anirban Gangopadhyay, met as high school students and later worked together as engineers at Palantir, according to The Next Web. The pitch to small employers is simple: plans that can be customised for companies with as few as two staff in some states, priced with more data than a conventional small group carrier uses.

The numbers behind the price

The company's disclosed metrics are unusually concrete for a private insurer, although none of them is audited. Angle Health says it serves more than 5,000 employers across 47 states, oversees close to $1bn in annualised premium equivalents and grew 120% over the past year. It also says it has been profitable for four consecutive quarters on both an EBITDA and a GAAP net income basis. When it announced a $134m Series B in December, which combined debt and equity and was led by Portage, it reported more than 3,000 employers in 44 states, according to MedCity News.

The most commercially important claim concerns price. Angle Health says median renewal increases for its customers have run at 5% to 7%, against a median of about 18% for small and midsize businesses in a Morgan Health study published in June. If that gap holds, it is the kind of advantage that brokers notice and that sticks, because renewal shocks are the main reason small employers switch carriers.

A useful way to read the valuation is against premiums rather than revenue. At $2.7bn, the company is valued at roughly 2.7 times the annualised premium equivalents it oversees. For a business whose gross flows are mostly claims paid out to hospitals and doctors, that is a high multiple, and it rests on the belief that underwriting technology will keep its loss ratios lower than those of incumbents as it grows.

Why most of the money goes to sellers

The $400m tender is aimed at early seed and Series A investors and at employees, according to HIT Consultant. The Wall Street Journal reported, as cited by The Next Web, that the secondary portion was priced at $2.5bn, below the headline figure, and that the new valuation is more than double the Series B mark set less than ten months ago.

There are sensible reasons for this design. A profitable company does not need large amounts of fresh equity, and raising only $200m of primary capital limits dilution. Insurers do need capital to support growth in premiums, but a business that is already generating earnings can fund part of that itself. Meanwhile, employees who joined a company founded in 2019 have waited a long time for liquidity, and a tender is a way to keep them without an initial public offering.

The discount on the secondary also matters. Buyers of secondary shares typically receive ordinary or older classes of stock with fewer protections than the preferred shares issued in a primary round. A gap of about 7% between the two prices is modest, which suggests that the new investors see limited downside in the existing capital structure.

The risks of underwriting with software

Venture investors have been burnt by insurance before. A previous generation of technology-led insurers raised large sums, grew quickly and then discovered that the cost of claims, not the quality of their apps, determined their results. Several of them struggled when they took on risk in the individual and Medicare Advantage markets. Angle Health's choice of small employer groups is a different bet, but the core discipline is the same: pricing risk correctly year after year.

Three things could test the model. First, rapid growth tends to bring in customers whose claims history is less well understood, and the company's profitability record covers only four quarters. Second, the backdrop is hostile. The company itself points to the steepest rise in employer health costs in two decades, and The Next Web cites a WTW projection of an 11.1% increase in US employer health costs in 2027. Lower renewals are easier to deliver when a book is young and healthy than when it ages. Third, level-funded plans depend on stop-loss cover and on regulation that varies by state, and any tightening of the rules on small group products would hit the whole segment.

Our view

Angle Health deserves credit for showing profits before asking for a higher price, and Vitruvian, an investor known for backing Wise, Skyscanner and Darktrace, has paid for a business with real operating data rather than a plan. But investors should be clear about what this round is. Two thirds of it is liquidity for existing holders, priced below the headline figure, and the $2.7bn mark therefore applies to a relatively small amount of new money. For founders, the lesson is that profitable companies can now command growth investor attention and arrange large tenders without listing, which is useful leverage in negotiations. For investors, the figures to watch are the loss ratio as the book passes $1bn in premiums, whether renewal increases stay in single digits during a year of rising medical costs, and whether the company starts to disclose audited numbers. Insurance rewards patience and punishes optimism about claims. If Angle Health can keep its pricing edge for three more years, today's valuation will look conservative. If not, the early holders who sold this month will have timed it well.

Sources

• Business Wire via 01net: Angle Health Raises $600 Million at a $2.7 Billion Valuation to Continue Expanding Affordable Healthcare Access for Small Businesses
• TechCrunch: Y Combinator insurance tech alum Angle Health hits $2.7B valuation
• The Next Web: Ex-Palantir engineers raise $600m to take on US health insurers
• HIT Consultant: Angle Health secures $600M financing led by Vitruvian Partners
• Pulse 2.0: Angle Health raises $600 million at $2.7 billion valuation to expand AI-native healthcare benefits platform
• MedCity News: Angle Health raises $134M Series B

Filed under Startups. Written by Invest Times Editorial under our editorial standards. Commentary and analysis for information only, not investment advice.